Earnings summaries and quarterly performance for AtriCure.
Executive leadership at AtriCure.
Michael H. Carrel
Detailed
President and Chief Executive Officer
CEO
AL
Angela L. Wirick
Detailed
Chief Financial Officer
DJ
Douglas J. Seith
Detailed
Chief Operating Officer
JJ
Justin J. Noznesky
Detailed
Chief Marketing and Strategy Officer
KS
Karl S. Dahlquist
Detailed
Chief Legal Officer
SP
Salvatore Privitera
Detailed
Chief Technical Officer
VD
Vinayak Doraiswamy
Detailed
Chief Scientific Officer
Board of directors at AtriCure.
Research analysts who have asked questions during AtriCure earnings calls.
Marie Thibault
BTIG
4 questions for ATRC
Also covers: ABT, ARAY, BSX +15 more
SK
Suraj Kalia
Oppenheimer & Co. Inc.
4 questions for ATRC
Also covers: ABT, AORT, BFLY +14 more
DA
Danielle Antalffy
UBS Group AG
3 questions for ATRC
Also covers: ABT, BAX, BSX +15 more
Daniel Stauder
Citizen JMP
3 questions for ATRC
Also covers: AORT, AVNS, LMAT +2 more
LL
Lilia-Celine Lozada
JPMorgan Chase & Co.
3 questions for ATRC
Also covers: BVS, CBLL, IART +4 more
MO
Matthew O'Brien
Piper Sandler & Co.
3 questions for ATRC
Also covers: APYX, ATEC, BBNX +18 more
Michael Matson
Needham & Company
3 questions for ATRC
Also covers: AORT, CNMD, ENOV +22 more
William Plovanic
Canaccord Genuity
3 questions for ATRC
Also covers: CBLL, CVRX, DXCM +9 more
John McAulay
Stifel
2 questions for ATRC
Also covers: AORT, PROF
DA
Danielle Antalffy
UBS
1 question for ATRC
Also covers: BSX, DXCM, JNJ
FW
Frederick Wise
Stifel
1 question for ATRC
Also covers: AORT, AVNS, BDX +13 more
Joseph Conway
Needham & Company, LLC
1 question for ATRC
Also covers: AORT, ENOV, HOLX +6 more
Lilly Quezada
JPMorgan Chase & Co.
1 question for ATRC
Zachary Day
Canaccord Genuity
1 question for ATRC
Also covers: TMDX
Recent press releases and 8-K filings for ATRC.
AtriCure Reports Preliminary 2025 Results and Provides 2026 Guidance
ATRC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- AtriCure reported preliminary fourth quarter 2025 revenue of $140.5 million, reflecting 13% growth, and full year 2025 revenue of $534.5 million, representing 15% growth over 2024.
- The company achieved positive adjusted EBITDA of approximately $57 million to $59 million for full year 2025 and ended the year with approximately $167 million in cash and investments.
- Management projects 2026 revenue of approximately $600 million to $610 million, reflecting 12% to 14% growth over full year 2025, and anticipates positive adjusted EBITDA of approximately $80 million to $82 million in 2026.
- AtriCure expects positive full year net income and projects continued positive cash flow in 2026.
Jan 16, 2026, 4:40 PM
AtriCure Highlights Strong Growth, Market Expansion, and Future Profitability at J.P. Morgan Healthcare Conference
ATRC
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- AtriCure (ATRC) anticipates its total annual market opportunity to grow from $1 billion to over $10 billion, with cardiac surgery alone representing an over $7 billion annual opportunity and pain management an over $2 billion opportunity.
- The company reported 15% overall growth and an 86% increase in positive EBITDA for 2025, with adjusted EBITDA reaching $57-$59 million. AtriCure expects to generate net income for the first time in 2026 and projects 12%-14% growth for 2026.
- Future growth is expected to accelerate significantly from ongoing clinical trials, LeAAPS and BOX-no-AF, which are ahead of schedule and aim to establish ablation and clip procedures as the standard of care for all cardiac surgery patients.
- AtriCure is ahead of its long-term plan to become a $1 billion company with a 20% operating margin on an EBITDA basis by the end of the decade.
Jan 14, 2026, 6:30 PM
AtriCure Discusses Market Opportunity, Growth Drivers, and 2026 Guidance at J.P. Morgan Conference
ATRC
Guidance Update
Product Launch
New Projects/Investments
- AtriCure (ATRC) highlighted a $10 billion annual market opportunity for its AFib and pain management solutions, with less than 10% penetration in the global cardiac surgery market.
- The company achieved 15% overall growth in 2025, with adjusted EBITDA increasing by 86% to $57-$59 million.
- For 2026, AtriCure projects 12%-14% revenue growth and $80-$82 million in adjusted EBITDA, anticipating its first year of net income profitability.
- Growth is driven by product innovations such as the EnCompass Clamp, Flex Mini, and Cryo XT, and ongoing clinical trials (LeAAPS and BOX-NO-AF) expected to establish new standards of care for cardiac surgery patients.
- Q4 2025 saw strong performance in cryo nerve block and open ablation/clip segments, with the hybrid business showing its first sequential revenue increase in a long time, despite international budget pressures.
Jan 14, 2026, 6:30 PM
AtriCure Reports Strong Annual Growth and Provides Positive 2026 Financial Guidance
ATRC
Guidance Update
Revenue Acceleration/Inflection
Product Launch
- AtriCure reported 15% overall growth and an 86% increase in positive EBITDA for the past year, generating $44 million in cash.
- The company provided 2026 revenue growth guidance of 12%-14% and adjusted EBITDA guidance of $80-$82 million, anticipating net income for the first time in 2026.
- AtriCure is addressing a $10 billion annual market opportunity by focusing on reducing AFib and pain after surgery, driven by product innovations such as the Encompass Clamp, Flex Mini, and the newly launched Cryo XT.
- Strategic clinical trials, LeAAPS and BOX-no-AF, are expected to expand market penetration and establish new standards of care for cardiac surgery patients, with data anticipated to accelerate growth in the latter half of the decade.
- Fourth quarter performance included strong growth in cryo nerve block, open ablation, and open atrial clip, though it experienced pressure from the U.K. market and continued challenges in the hybrid business, which showed a sequential uptick.
Jan 14, 2026, 6:30 PM
AtriCure Reports Preliminary Q4 and Full Year 2025 Results, Provides 2026 Financial Outlook
ATRC
Earnings
Guidance Update
- AtriCure, Inc. announced its preliminary financial results for the fourth quarter and full year 2025.
- The company also provided its 2026 financial guidance.
- Preliminary, unaudited revenue for the fourth quarter of 2025 is expected to be $140.5 million, reflecting approximately 13% growth over the fourth quarter of the previous year.
Jan 12, 2026, 3:21 PM
AtriCure Reports Preliminary Q4 and Full Year 2025 Results, Provides 2026 Outlook
ATRC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- AtriCure announced preliminary unaudited revenue for Q4 2025 is expected to be $140.5 million, reflecting approximately 13% growth over Q4 2024.
- For full year 2025, preliminary unaudited revenue is expected to be $534.5 million, an approximate 15% growth over full year 2024. The company also expects full year 2025 adjusted EBITDA of approximately $57 million to $59 million and an adjusted loss per share of approximately $0.18 to $0.21.
- Management projects 2026 revenue of approximately $600 million to $610 million, reflecting 12% to 14% growth over full year 2025.
- For 2026, the company anticipates positive adjusted EBITDA of approximately $80 million to $82 million and expects full year net income.
Jan 12, 2026, 3:21 PM
AtriCure Reports Preliminary Q4 and Full Year 2025 Results and Provides 2026 Financial Outlook
ATRC
Earnings
Guidance Update
- AtriCure reported preliminary, unaudited Q4 2025 revenue of $140.5 million, an increase of approximately 13% over Q4 2024, and full year 2025 revenue of $534.5 million, up approximately 15% over full year 2024.
- For full year 2025, the company expects adjusted EBITDA between $57 million and $59 million and an adjusted loss per share of $0.18 to $0.21.
- AtriCure provided 2026 financial guidance, projecting revenue of $600 million to $610 million (12% to 14% growth), adjusted EBITDA of $80 million to $82 million, and anticipates full year net income.
- The company also amended its Credit Agreement, extending the term by three years, reducing the interest rate, and maintaining an asset-based revolving credit facility of up to $125 million for working capital and general corporate purposes.
Jan 12, 2026, 1:00 PM
AtriCure Inc. (ATRC) 2025 Product Pipeline Analysis and Recent Developments
ATRC
Product Launch
New Projects/Investments
- AtriCure Inc. (ATRC), a medical technology company, specializes in treatments for atrial fibrillation (Afib) with a product portfolio featuring Isolator Synergy, AtriClip, Hybrid AF Therapy, and cryoICE cryoSPHERE technologies.
- In late 2025, AtriCure announced significant product developments, including treating the first patients with a novel dual energy platform and in the BoxX-NoAF study, and securing additional FDA 510(K) clearance for its Isolator Synergy Encompass Clamp.
- The company also completed enrollment in the LeAAPS Clinical Trial for stroke prevention in July 2025.
Jan 1, 2026, 5:18 PM
AtriCure Discusses Product Growth and Financial Outlook
ATRC
Product Launch
Revenue Acceleration/Inflection
Guidance Update
- AtriCure's Flex Mini clip, launched in Q4 last year, significantly drove Q3 growth by 18.5% and has achieved over 30% system penetration, offering a price increase from $1,750 (Flex-V) to $2,250.
- The Encompass clamp accounts for over 50% of U.S. revenue , and the Box No AF trial, with approximately 1,000 patients, aims to reduce post-operative AFib from 35-40% to under 10%, with initial data anticipated around early 2028.
- The pain management business, boosted by cryoSPHERE MAX, is targeting substantial markets including 150,000 thoracic and 250,000 sternotomy procedures, and 90,000 lower limb amputations for the $3,500 XT device.
- The company is focused on achieving 100 basis points of annual EBITDA margin expansion and mid-teens revenue growth, aiming for $1 billion in revenue by the end of the decade, with potential for net income in Q4.
Dec 2, 2025, 3:00 PM
AtriCure Highlights Product Innovation and Market Expansion with Strong Financial Performance
ATRC
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- AtriCure's clip business experienced 18.5% growth in Q3, an acceleration over the prior six quarters, driven by the Flex Mini product, which is 60% smaller and has achieved 30% penetration in systems in months. The Flex Mini carries an average selling price (ASP) of $2,250, an increase from the Flex-V's $1,750.
- The Encompass clamp now contributes over 50% of US revenue and has significantly reduced procedure times from 30-40 minutes to under 10 minutes.
- The company's Box No AF trial, involving approximately 1,000 patients, aims to reduce post-operative AFib from 35-40% to below 10%. Enrollment is currently exceeding internal goals, with initial data potentially leading to an advanced label.
- The pain management business is performing well, fueled by cryoSPHERE MAX and the new XT device for amputation pain, which targets a US market of 180,000-190,000 amputations at an ASP of approximately $3,500.
- AtriCure achieved a $25 million EBITDA improvement this year, surpassing its annual goal of 100 basis points of EBITDA margin expansion, and anticipates potential net income in Q4. The company projects mid-teens revenue growth with a long-term target of $1 billion by the end of the decade.
Dec 2, 2025, 3:00 PM
Quarterly earnings call transcripts for AtriCure.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more